Neuren (Drug developer focused on Orphan neurological disorders)

This drug developer’s lead candidate is Trofinetide, which is in Phase 3of the treatment of an Orphan disorder called Rett syndrome and in Phase 2 for Fragile X syndrome. The North American rights to Trofinetide were licensed to the American biotech company, Acadia Pharmaceuticals in mid-2018 for US$455m in potential clinical and commercial milestone payments, and royalties after that. Neuren has a pipline of opportunities at pre-clinical.